0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Quantitative risk-benefit analysis of natalizumab.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS).

          Related collections

          Author and article information

          Journal
          Neurology
          Neurology
          Ovid Technologies (Wolters Kluwer Health)
          1526-632X
          0028-3878
          Jul 29 2008
          : 71
          : 5
          Affiliations
          [1 ] Department of Neurology, University of Rochester, Rochester, NY, USA.
          Article
          71/5/357
          10.1212/01.wnl.0000319648.65173.7a
          2676947
          18663181

          Comments

          Comment on this article